NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results

Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV expands worldwide potential of novel radioenhancer NBTXR3Prolonged survival in Study 102 reinforces...

Related Keywords

United States ,Cambridge ,Cambridgeshire ,United Kingdom ,France ,Texas ,Massachusetts ,New York ,Paris ,France General ,French ,American ,Brandon Owens ,Kevin Gardner ,Laurent Wormser ,Bart Van Rhijn ,Louis Kayitalire ,Euronext ,American Association For Cancer Research ,Investor Relations Department ,Johnson ,Exchange Commission ,Linkedin ,Development Rd Expenses ,Communications Department ,Jjdc Inc ,Given The Company ,Twitter ,Nasdaq ,University Of Texas Md Anderson Cancer Center ,European Society For Medical Oncology ,Drug Administration ,Janssen Pharmaceutica ,Registration Document ,Annual Report ,Laurent Levy ,Johnson Innovation ,Subsequent Events ,Pipeline Status ,Chief Medical Officer ,Advanced Head ,Neck Squamous Cell Carcinoma ,Local Control ,Single Agent Activated ,Annual Meeting ,American Society ,Radiation Oncology ,European Society ,Medical Oncology ,All Patients Treated ,Metastatic Head ,Priming Immune Response Followed ,Strategic Collaboration ,Cancer Center ,Validate Tumor Agnostic ,Combination Agnostic Therapeutic ,American Association ,Cancer Research ,Pancreatic Cancer ,Cash Equivalents ,Full Year ,United States Food ,Fast Track ,Euronext Paris ,Nasdaq Global Select Market ,New York City ,Private Securities Litigation Reform Act ,Markets ,